Impact of Extending Beta-Lactam Infusions on IV Access Requirements by Kirstin J. Kooda, PharmD, Julia Nelson, BS, Sara E. Ausman, PharmD, Christina G. Rivera, PharmD, Omar M. Abu Saleh, MBBS, Andrew D. Rule, MD, Ryan W. Stevens, PharmD, Micaela N. Warfield, PharmD, Yanjun Zhao, PharmD, Erin F. Barreto, PharmD, PhD, on behalf of the Beta Lactam Optimization and Outcomes Management (BLOOM) Study Group, Laura M. Dinnes, PharmD, Ognjen Gajic, MD, Laurie A. Meade, RN, Rebecca J. Wessel, DPT, MBA.

Get full text